Klin Farmakol Farm. 2008;22(3):94-98

Risk therapy perception and adhesion to secondary pharmacotherapy after myocardial infarction

Monika Laššánová, et. al
Farmakologický ústav Lekárskej fakulty UK, Bratislava

The aim of the presented study was to analyze reported adverse drug reaction (ADR) and number of prescribed drugs among patients after myocardial infarction (MI). We evaluated the adherence of doctors to guidelines for secondary prevention after IM, and adherence to using of four Evidence Based Medicine (EBM) drug groups (antithrombotic drugs, ACE inhibitors, beta-blockers and lipid lowering drugs) and their combination after IM.

Method: Statistical processing of 103 patients with IM, which were hospitalized at the I. Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, during the year 1999, and their other hospitalization on this Department till September 2005.

Results: In studied group of patients, there were seven reported ADR. We observed important increase of total number of drugs, which were prescribed in discharge into ambulatory care opposite in the beginning of hospitalization (p<0,001). During hospitalization or after discharge has come up to positive significant increase (p<0,001) of prescription of antithrombotic drugs, ACE inhibitors, beta-blockers and lipid lowering drugs and also to the significant increase in use three or four EMB groups. Conslusions: Our results point out on the fact that the hospitalization led to increase of number of drugs, which were prescribed in discharge into ambulatory care. Adherence of doctors to guidelines for secondary prevention after IM is good. There is significant increase of prescription such EBM drugs as antithrombotic drugs, ACE inhibitors, beta-blockers and lipid lowering drugs and also the significant increase in use three or four EMB groups in discharge. In the evaluated group we have observed insufficient prescription of beta-blockers and lipid lowering drugs.

Keywords: Key words: myocardial infarction, Evidence Based Medicine, adverse drug reaction, antithrombotic drugs, ACE inhibitors, beta-blockers, statins.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Laššánová M, al E. Risk therapy perception and adhesion to secondary pharmacotherapy after myocardial infarction. Klin Farmakol Farm. 2008;22(3):94-98.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002; 50(12): 1962-1968. Go to original source... Go to PubMed...
    2. Davies EC, Green CF, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther. 2006; 31: 335-341. Go to original source... Go to PubMed...
    3. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006; 4(1): 36-41. Go to original source... Go to PubMed...
    4. Krähenbühl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krähenbühl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007; 30(5): 379-407. Go to original source... Go to PubMed...
    5. Adamcik BA, Rhodes RS. The Pharmacist's Role in Rational Drug Therapy of the Aged. Drugs Aging. 1993; 3(6): 481-448. Go to original source... Go to PubMed...
    6. Nikolaus T, et al. Elderly patient´s problems with medications. An in-hospital and follow-up study. Eur J Clin Pharmacol. 1996; 49: 255-259. Go to original source... Go to PubMed...
    7. Sackett DL, Strauss SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and Teach EBM, 2nd Edition. New York, Churchill Livingstone, 2000; 261 s.
    8. Scholten RJ, Clarke M, Hetherington J. The Cochrane Collaboration. Eur J Clin Nutr. 2005; 59 (Suppl 1): S147-149. Go to original source... Go to PubMed...
    9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44: E1-211.
    10. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44: E1-211. Go to original source... Go to PubMed...
    11. Smith SC, Allen J, Blair SN, et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update, endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363-2372. Go to original source... Go to PubMed...
    12. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004; 109: 745-749. Go to original source... Go to PubMed...
    13. Timóteo AT, Fiarresga A, Feliciano J, et al. Impact of combination medical therapy on mortality in patients with acute coronary syndromes. Rev Port Cardiol. 2006; 25(12): 1109-1118. Go to PubMed...
    14. Anonymous. Úrad verejného zdravotníctva SR. Informácia o aktualizácii NPPZ vrátane výsledkov o zdravotnom uvedomení obyvateľstva. Dostupné na: http://www.uvzsr.sk/vypis_clanku.html?cast=1-4672&polozka_id=2989173&cast=1-4672. (Dostupnosť overená 5. júna 2008).
    15. Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol. 2004; 94: 25-29. Go to original source... Go to PubMed...
    16. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006; 113 (2): 203-212. Go to original source... Go to PubMed...
    17. Di Chiara A, Chiarella F, Savonitto S, et al. BLIT Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network. Eur Heart J. 2003; 24(18): 1616-1629. Go to original source... Go to PubMed...
    18. Yap YG, Duong T, Bland JM, et al. Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction-a combined analysis from multicenter trials. Clin Cardiol. 2005; 28(10): 471-478. Go to original source... Go to PubMed...
    19. van den Bemt PM, Egberts TC, de Jong-van den Berg LT, Brouwers JR. Drug-related problems in hospitalised patients. Drug Saf. 2000; 22(4): 321-333. Go to original source... Go to PubMed...
    20. Wawruch M, Zikavska M, Wsolova L, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharm World Sci. 2008; 30(3): 235-242. Go to original source... Go to PubMed...
    21. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004; 57(2): 121-126. Go to original source... Go to PubMed...
    22. Anonymous. Antithrombotic Trialists´ Collaborations. Collaborative meta-analysis of randomised trials of antipalatet therapy for prevention of death, myocardial infarction, and stroke in hight risk patients. BMJ. 2002; 324: 71-86. Go to original source... Go to PubMed...
    23. Gouya G, Reichardt B, Ohrenberger G, Wolzt M. Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol. 2007; 22(3): 145-149. Go to original source... Go to PubMed...
    24. Gajdošík J, Kriška M. Poznáme skutočnú ochotu pacientov dodržiavať rady lekára? Praktický lékař. 2005; 85(2): 108-112.
    25. Anonymous. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001; 22(7): 554-572. Go to original source... Go to PubMed...
    26. Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002; 23(15): 1177-1189. Go to original source... Go to PubMed...
    27. Simpson E, Beck C, Richrd H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003; 145: 438-444. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.